XASX
CQT
Market cap10mUSD
Oct 17, Last price
0.03AUD
Name
CardieX Ltd
Chart & performance
P/E
—
P/S
2.36
EPS
—
Div yield, %
—
Shrs. gr., 5y
34.24%
Rev. gr., 5y
7.92%
Revenues
6m
-42.39%
Net income
-13m
L+95.49%
CFO
-11m
L+41.12%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
CardieX Limited, established in Sydney, Australia, in 1994, is a global innovator specializing in the design, production, and distribution of medical devices for cardiovascular health management. Operating across the Americas, Europe, and the Asia Pacific, the company collaborates with pharmaceutical firms by providing its advanced SphygmoCor XCEL devices. It also delivers comprehensive laboratory and data management services, ensuring high-quality datasets for clinical trial sponsors. Under its CONNEQT brand, CardieX develops cutting-edge home vascular health solutions, which encompass remote patient monitoring, tools for decentralized clinical trials, specialized wearables, and medical applications. A flagship product is the CONNEQT Pulse device, a home-based system that leverages proprietary SphygmoCor technology to precisely measure central blood pressure, arterial waveforms, and other vital arterial health parameters. CardieX serves a diverse clientele, including hospitals, clinics, research institutions, and pharmaceutical companies. The company also maintains a strategic alliance with LifeQ, Inc., focusing on wearable device technology. CardieX Limited was formerly known as AtCor Medical Holdings Limited until its name change in June 2018.
Key people
Interim Non-Executive Chairman of the Board · since 2019
Craig Cooper
Chief Executive Officer, Executive Director · since 2017
Chris Dax
President of AtCor Medical · since 2019
Rhonda Welch
Vice President of Global Marketing · since 2019
Douglas Kurschinski
General Manager and Head of Global Sales of AtCor · since 2019
Duncan R. Ross
Managing Director, Executive Director · since 2017
Mark Harding
Vice President, Global Marketing & International Sales AtCor Medical Pty Ltd · since 2008
Chief Financial Officer, Company Secretary · since 2005
Jarrod White
Chief Financial Officer, Company Secretary, Director · since 2020
Randall King Nelson
Independent Non-Executive Director · since 2015
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||